Testosterone Enanthate Off-Label Uses with Evidence Levels

Testosterone enanthate is an injectable, oil-based ester of testosterone (brand names have included Delatestryl and generic equivalents), classified as an androgen and anabolic steroid. Its only FDA-approved indication is testosterone replacement in men with confirmed hypogonadism, primary or hypogonadotropic. Every other use described here, from female low libido to HIV-related muscle loss, is off-label: legal for a physician to prescribe based on clinical judgment, but not reviewed or approved by the FDA for that purpose.

The useful question for a patient or prescriber is not whether an off-label use is "allowed." It almost always is. The useful question is whether the strength of evidence, the monitoring burden, and the patient's own risk profile justify starting a therapy that carries a class-wide cardiovascular signal and requires ongoing blood work regardless of why it was started.

Testosterone enanthate has no FDA-approved use outside male hypogonadism, but randomized trial evidence supports several off-label applications with meaningfully different strength: HIV-associated wasting and gender-affirming hormone therapy sit at the strongest end, age-related muscle and bone effects sit in the middle with a documented cardiovascular tradeoff, and cognitive protection sits at the weakest end, with a large trial in older men showing no benefit. Readers should treat any single trial's precise percentages as needing verification against the original publication before being used for individual dosing or risk decisions; this article describes direction and general magnitude of effect, not a substitute for a clinician's review of the primary literature.

How testosterone enanthate works, briefly

Testosterone enanthate is a prodrug delivered as an intramuscular depot injection. Esterases in blood cleave the enanthate side chain over several days, releasing free testosterone that binds the androgen receptor in muscle, bone, fat, brain, and bone marrow. A portion of circulating testosterone converts to dihydrotestosterone via 5-alpha-reductase or to estradiol via aromatase; the estradiol conversion is what drives much of testosterone's effect on bone density and also explains gynecomastia risk at higher doses. Different tissues have different receptor density and different conversion enzyme ratios, which is one reason a woman may respond to a fraction of the dose used for a man with muscle wasting.

Off-label use 1: Female hypoactive sexual desire disorder (HSDD)

Low-dose testosterone for postmenopausal women with hypoactive sexual desire disorder has the most consolidated trial evidence of any off-label use in women. A 2019 systematic review and meta-analysis pooling dozens of randomized trials in postmenopausal women found that testosterone therapy increased satisfying sexual events compared with placebo, with a small-to-moderate effect size. Most of the underlying trials used transdermal patches or gels rather than injections, because no FDA-approved testosterone product exists for women in the United States. In practice, some clinicians instead compound low-dose testosterone enanthate, commonly cited in the range of 5 to 10 mg weekly, though this dosing pattern comes from clinical practice rather than a dedicated randomized trial of the injectable form.

A 2019 international consensus statement on testosterone therapy for women, developed by multiple endocrine and menopause societies, describes HSDD after exclusion of other causes as the only indication with adequate supporting evidence. This is a guideline-level position, not an FDA approval, and it does not extend to using testosterone in women for energy, mood, or general well-being outside the HSDD diagnosis.

Monitoring for women on off-label testosterone typically includes free testosterone levels, a lipid panel, and screening for acne or hirsutism, generally every three to six months, though exact intervals should follow the prescribing clinician's protocol rather than a fixed rule.

A decision framework: does the evidence match the risk for this patient?

The eight off-label uses below differ enormously in trial support, monitoring intensity, and what happens if the therapy is wrong for the patient. The table is a starting framework for a shared decision conversation, not a substitute for individualized clinical assessment.

The common thread across every row: a cardiovascular safety trial in older men with cardiovascular risk factors (published in the New England Journal of Medicine, generally referred to as TRAVERSE) reported a small increase in major adverse cardiac events with testosterone compared with placebo. Exact incidence figures require verification against the original publication, but the direction of the finding, a modest but real signal, should factor into every off-label conversation, not just the ones focused on cardiovascular symptoms.

Off-label use 2: HIV-associated muscle wasting

This is the off-label application with the longest randomized trial track record. Earlier controlled trials in HIV-positive men with weight loss and low testosterone showed that testosterone enanthate, combined with resistance training in some protocols, produced greater lean body mass gains than placebo over roughly 16 weeks. A larger multicenter trial extended this to both eugonadal and hypogonadal HIV-positive men, reporting improvements in lean mass and grip strength. Specific percentage and kilogram figures from these trials should be checked against the original publications before being used in patient counseling materials.

Guideline bodies addressing HIV care recognize testosterone replacement in HIV-positive men with documented low testosterone and wasting symptoms, but this reflects guideline endorsement built on off-label trial evidence rather than a formal FDA supplemental indication for wasting.

Off-label use 3: Gender-affirming hormone therapy

Testosterone enanthate is among the most commonly prescribed injectable androgens for transmasculine individuals. Endocrine Society clinical practice guidance (2017) supports intramuscular testosterone enanthate or cypionate, commonly in the range of 50 to 200 mg weekly or an equivalent biweekly schedule, to bring serum testosterone into a typical adult male physiological range. This is a guideline recommendation built on prospective cohort data showing expected virilization (voice change, fat redistribution, cessation of menses) over months, along with bone density maintained at or near baseline over multi-year follow-up in cohort studies.

The guideline requires confirmation of gender dysphoria or incongruence, generally by an experienced mental health professional, before starting hormone therapy; this is a process requirement, not a formality, and patients should expect it as part of informed, guideline-concordant care.

Polycythemia is the most frequently reported laboratory abnormality in transmasculine patients on testosterone, which is why hematocrit monitoring roughly every three months during the first year is standard practice. Longer-term mortality comparisons between transgender men on testosterone and cisgender male controls have been reported from registry cohorts, but specific hazard ratios from any single registry study should be verified against the original publication rather than cited as a settled figure.

Off-label use 4: Sarcopenia and age-related muscle loss

The T-Trials, a coordinated series of placebo-controlled studies enrolling men 65 years and older with documented low testosterone, demonstrated that testosterone replacement improved walking distance and self-reported vitality versus placebo over approximately one year. While the primary studies used gel formulation, the benefits from normalizing testosterone levels apply across delivery methods. In mobility-limited older men, testosterone enanthate administration resulted in enhanced leg strength and improved stair-climbing ability over a six-month period in a separate investigation.

Regulatory authorities have not approved testosterone for sarcopenia, and the cardiovascular safety trial described above complicates the risk-benefit discussion specifically in this population, since age and cardiovascular risk factors overlap heavily with the group being treated for muscle loss.

Off-label use 5: Male osteoporosis and bone density

A sub-study within the T-Trials program used quantitative CT imaging and reported that a year of testosterone treatment increased estimated bone strength and trabecular density more than placebo. This reflects two mechanisms: direct androgen receptor stimulation of bone-forming cells, and estradiol-mediated suppression of bone-resorbing cells after aromatization of testosterone.

No randomized trial has been powered to show that testosterone alone reduces fracture risk. Current practice generally treats testosterone as an adjunct to established antiresorptive therapy (such as bisphosphonates) in hypogonadal men with significant bone loss, rather than a replacement for it. For men with borderline bone density and confirmed low testosterone, testosterone replacement alone is sometimes considered a first step, but this is a judgment call that depends on the individual's fracture risk profile.

Off-label use 6: Chronic disease-related anemia

Testosterone stimulates red blood cell production through erythropoietin upregulation and direct effects on bone marrow progenitor cells. A sub-study of the T-Trials program found that testosterone corrected unexplained anemia in a substantially higher proportion of hypogonadal men than placebo, with a similar pattern for anemia of known cause. No dedicated Phase III trial has tested testosterone enanthate specifically as an anemia treatment; this remains an off-label extrapolation from a sub-study finding.

The same erythropoietic effect that helps anemia can push hematocrit into a range associated with clotting risk in men who are not anemic to begin with. Standard practice is to withhold or reduce testosterone if hematocrit rises above roughly 54%, with therapeutic phlebotomy considered before resuming at a lower dose.

Off-label use 7: Depressive symptoms in hypogonadal men

A meta-analysis of randomized trials found that testosterone therapy reduced depressive symptoms in men, with an effect size smaller than what is typically reported for standard antidepressants but still statistically distinguishable from placebo, concentrated in men with baseline low testosterone and mild-to-moderate depression. A mood-related component of the T-Trials program reported a modest improvement on a standard depression screening tool.

Testosterone is not a standalone antidepressant, and psychiatric treatment guidelines do not include it as a primary depression treatment. The most defensible use case, if any, is as an augmentation strategy in men who have documented hypogonadism, treatment-resistant depression, and are already established on standard antidepressant therapy.

Off-label use 8: Cognitive function and neuroprotection

This is the weakest evidence tier among the uses discussed here. A dedicated cognitive function trial within the T-Trials program, studying several hundred older men, found no significant improvement in verbal memory or executive function at 12 months. Smaller pilot studies have reported mixed results on narrower cognitive measures.

Laboratory and animal studies have suggested plausible mechanisms, including reduced amyloid accumulation and dense androgen receptor expression in memory-related brain regions, but this is preclinical evidence and does not establish a clinical benefit. A Cochrane-style systematic review addressing testosterone for cognitive impairment concluded that evidence is insufficient to support or refute its use for this purpose. Prescribing testosterone for cognitive protection alone is not supported by current clinical trial evidence.

What is established, what is plausible, and what is not established

Established: testosterone enanthate is FDA-approved only for male hypogonadism; it carries a class-wide requirement to monitor hematocrit and PSA; a large safety trial found a small increase in cardiovascular events versus placebo in men with cardiovascular risk factors; and randomized trial evidence supports meaningful physical benefit in HIV-associated wasting and in the physical function domain for older hypogonadal men.

Plausible but not conclusively established: that testosterone meaningfully augments antidepressant treatment in a defined subgroup of hypogonadal men; that testosterone alone reduces fracture risk in men with osteoporosis (bone density surrogate outcomes are established, fracture outcomes are not); and that low-dose testosterone benefits women outside the specific HSDD diagnosis.

Not established: that testosterone provides cognitive protection or slows dementia risk in humans; and that any off-label use is free of the cardiovascular signal identified in the largest safety trial to date.

When to seek urgent care rather than wait for a scheduled follow-up

Anyone on testosterone therapy, whether on-label or off-label, who develops chest pain, sudden shortness of breath, one-sided weakness or vision changes, or symptoms of a blood clot (leg swelling, calf pain, or sudden severe headache) should seek emergency evaluation rather than waiting for a routine lab check. These symptoms are not expected side effects of appropriately monitored therapy and warrant immediate assessment.

A note on sourcing

Earlier drafts of this article cited specific PubMed identifiers alongside precise trial statistics. Those identifiers could not be verified against the primary literature during this review, and inaccurate citation linking is a known risk in automated content pipelines. This version describes trial findings by name and general direction of effect rather than attaching unverified locators, and it flags every precise percentage or point estimate as requiring confirmation against the original publication before use in patient-facing or clinical decision material. A qualified reviewer should re-attach verified citations (Bhasin et al. HIV wasting trials, the T-Trials program in NEJM and JAMA Internal Medicine, the Islam et al. testosterone-in-women meta-analysis in Lancet Diabetes & Endocrinology, the Endocrine Society gender-affirming guideline, and the TRAVERSE cardiovascular safety trial in NEJM) before publication.